Form 4: TriSalus Life Sciences Executive Jennifer Stevens Reports Stock and Option Awards

Jennifer Stevens, Chief Regulatory Officer of TriSalus Life Sciences, reports the acquisition of restricted stock units and stock options.

Summary

• Jennifer Stevens, Chief Regulatory Officer of TriSalus Life Sciences, filed a Form 4 detailing changes in beneficial ownership.
• On January 27, 2025, Stevens was granted 10,625 restricted stock units (RSUs) and an option to purchase 63,750 shares of common stock.
• The RSUs vest in four equal annual installments starting January 1, 2025, contingent upon continued service.
• The stock options vest over four years, with one-fourth vesting on January 1, 2025, and the remainder vesting monthly thereafter, also contingent upon continued service.
• Following these transactions, Stevens directly owns 43,408 shares of TriSalus Life Sciences common stock and options to purchase 63,750 shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, suggesting a stable and incentivized management team. The sentiment is neutral to positive.

Positives

• The grant of RSUs and stock options to a key executive like the Chief Regulatory Officer suggests the company is incentivizing her to remain with the company and contribute to its long-term success.
• The vesting schedules for both the RSUs and stock options are tied to continued service, aligning the executive's interests with those of the shareholders.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the RSUs and stock options suggest an expectation of continued service from the executive.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the equity holdings of company insiders. The granting of stock options and RSUs is a common practice to align management's interests with those of shareholders in the biotech industry.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the biotech industry, often used to attract and retain talent.
• Vesting schedules tied to continued service are also common, aligning executive incentives with long-term company performance.
• Comparable companies like Amgen, Gilead, and Biogen also utilize stock options and RSUs as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with long-term value creation.
• Employees may see the grants as a sign of confidence in the company's future.

Key Dates